SAB has entered into a definitive merger agreement with Big Cypress Acquisition Corp. (NASDAQ: BCYP) Click to Read More

Click for Webcast Replay
RSS
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

September 8, 2021
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

August 11, 2021
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

July 9, 2021
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

July 8, 2021
Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics

Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics

July 7, 2021
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

June 29, 2021
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp.

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp.

June 22, 2021
SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021

SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021

June 14, 2021
SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs

SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs

June 10, 2021

SAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

May 14, 2021
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

April 21, 2021